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Depletion of immune elements before adoptive cell transfer (ACT) can dramatically improve 
the antitumor efficacy of transferred CD8
 
 
 
 T cells, but the specific mechanisms that 
contribute to this enhanced immunity remain poorly defined. Elimination of CD4
 
 
 
CD25
 
 
 
 
regulatory T (T reg) cells has been proposed as a key mechanism by which lymphodepletion 
augments ACT-based immunotherapy. We found that even in the genetic absence of T reg 
cells, a nonmyeloablative regimen substantially augmented CD8
 
 
 
 T cell reactivity to self-
tissue and tumor. Surprisingly, enhanced antitumor efficacy and autoimmunity was caused 
by increased function rather than increased numbers of tumor-reactive T cells, as would be 
expected by homeostatic mechanisms. The 
 
 
 
C
 
 cytokines IL-7 and IL-15 were required for 
augmenting T cell functionality and antitumor activity. Removal of 
 
 
 
C
 
 cytokine–responsive 
endogenous cells using antibody or genetic means resulted in the enhanced antitumor 
responses similar to those seen after nonmyeloablative conditioning. These data indicate 
that lymphodepletion removes endogenous cellular elements that act as sinks for cytokines 
that are capable of augmenting the activity of self/tumor-reactive CD8
 
 
 
 T cells. Thus, the 
restricted availability of homeostatic cytokines can be a contributing factor to peripheral 
tolerance, as well as a limiting resource for the effectiveness of tumor-specific T cells.
 
The immune system precisely controls the levels
and the activation state of each cellular com-
partment through homeostatic regulation, a
process triggered during development and after
the induction of a lymphopenic state (1–7). It
has been long observed in mice that depletion
of immune cells before adoptive cell transfer
(ACT) can considerably enhance the antitumor
efficacy of transferred CD8
 
 
 
 T cells (8–10).
Recently, lymphodepletion followed by ACT
has emerged as a promising treatment for patients
with metastatic solid cancer (11, 12), but the
molecular and cellular mechanisms that con-
tribute to this antitumor effect have not been
completely elucidated. Homeostatic expansion
and T cell activation have been proposed to
explain the enhanced antitumor responses seen
after ACT into lymphodepleted hosts (13, 14).
In addition, experiments indicate that lympho-
depletion may enhance the antitumor efficacy
of transferred CD8
 
 
 
 T cells by removal of
competition at the surfaces of APCs (7, 15). T
reg cells are critically involved in maintaining
immunological tolerance to self/tumor antigens
(16–20), and their removal is also considered a
key mechanism underlying the effectiveness of
lymphodepletion (21).
We describe the surprising finding that
the augmentation of the antitumor efficacy of
an ACT regimen after lymphodepletion is
not a result of increased numbers of tumor-
reactive T cells. Rather, lymphodepletion
acts by enhancing the effector functions of
transferred T cells. We demonstrate that the
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mere removal of T reg cell immune suppression is not the
only mechanism accountable for the enhanced antitumor
immunity observed after lymphodepletion: eradication of
cellular sinks and the resultant increase in the availability of
cytokines is also a central mechanism in activating self/
tumor antigen–specific CD8
 
 
 
 T cells.
 
RESULTS AND DISCUSSION
 
We have recently reported that an ACT regimen that com-
bines the transfer of TCR transgenic (Tg) CD8
 
 
 
 T cells
(pmel-1) reactive against the self/tumor antigen gp100, al-
tered ligand vaccination, and the administration of exoge-
nous IL-2 can cause substantial tumor regression of large,
established s.c. B16 melanoma (22). To determine whether
lymphodepletion could enhance antitumor immunity of
transferred CD8
 
 
 
 T cells, we evaluated this ACT regimen
(22) in tumor-bearing C57BL/6 WT hosts and hosts ren-
dered lymphopenic by nonmyeloablative sublethal 5-Gy
total body irradiation (TBI). In mice, TBI induced a severe
lymphopenia similar to that induced by a nonmyeloablative
chemotherapy regimen of 250 mg/kg Cytoxan 
 
 
 
 50 mg/
kg fludarabine (a combination currently used in the clinic;
Fig. 1 a) (11). Transfer of 10
 
7
 
 pmel-1 cells in combination
with vaccination and IL-2 can eradicate established B16 tu-
mors (22). We thus gave a log fewer (10
 
6
 
 cells in all exper-
iments) to generate a treatment window. Tumor treatment
was significantly improved in TBI compared with nonirra-
diated hosts (P 
 
  
 
0.0014) when this tripartite regimen was
used (Fig. 1 b).
No significant differences (P 
 
  
 
0.05) in tumor growth were
observed in untreated WT or TBI mice (Fig. 1 b), indicating
that irradiation did not act by directly killing the tumor but
rather acted as a result of its impact on host cells. Indeed, up to
20 Gy could be delivered directly to the tumor while shielding
the host with little effect (Fig. S1 a, available at http://
www.jem.org/cgi/content/full/jem.20050732/DC1). Con-
versely, shielding the tumor with irradiation delivered solely to
the host resulted in profound antitumor effects (Fig. S1 b). Be-
cause chemotherapy had some direct antitumor effect (unpub-
lished data), we chose to use TBI as a lymphodepleting regimen
in the following experiments.
Transfer of T cells into lymphopenic recipients results in
their proliferation and differentiation (3, 6, 7), but it was not
known whether homeostatic proliferation was the mechanism
responsible for the increased antitumor activity of pmel-1 cells
after TBI. Surprisingly, when the tripartite regimen was given
to tumor-bearing WT mice with TBI, we did not find an in-
creased number of pmel-1 cells. Similar numbers or percent-
ages of pmel-1 cells were found in the spleen (Fig. 1 c), blood
(Fig. 1 d), tumor (Fig. 1 e), and tumor-draining lymph nodes
(not depicted) of lymphodepleted and lymphoreplete animals.
In addition, kinetic analyses using bromodeoxyuridine label-
ing indicated that there were no important differences in cell
proliferation in nondepleted and lymphodepleted settings (un-
published data). Thus, the absolute number of tumor-reactive
CD8
 
 
 
 T cells alone did not explain the enhanced antitumor
responses into lymphodepleted recipients.
However, when pmel-1 CD8
 
 
 
 T cells were isolated
from the same animals and tested for antigen-specific func-
Figure 1. Lymphodepletion enhances antitumor efficacy of adop-
tively transferred CD8  T cells. (a) 5 Gy TBI induces severe lymphopenia. 
Mice were treated with 5 Gy TBI or a nonmyeloablative chemotherapy 
regimen with 250 mg/kg Cytoxan   50 mg/kg fludarabine. Absolute lympho-
cyte count was determined at the indicated time points. (b) Lymphodepletion 
augments antitumor responses. TBI or nonirradiated WT mice bearing 
12-d-old established s.c. B16 tumors were left untreated or received 
adoptive transfer of 106 cultured pmel-1 T cells in conjunction with 
rFPhgp100 vaccination and rhIL-2. Data shown are representative of 
multiple independent experiments. Values represent the mean   SEM. 
(c–e) Lymphodepletion does not result in increased numbers of adoptively 
transferred T cells. Absolute numbers of adoptively transferred pmel-1 
cells (CD8 Thy1.1 ) in the spleens (c) and in the blood (d) of tumor-bearing, 
TBI, and nonirradiated mice. Percentages of adoptively transferred pmel-1 
cells (CD8 Thy1.1 ) in the tumor (e) under conditions specified. (f–i). 
Lymphodepletion enhances effector functions of adoptively transferred 
T cells. 6 d after adoptive transfer, pmel-1 thy1.1  cells were isolated from 
the spleens of irradiated and nonirradiated mice and co-cultured with 
irradiated splenocytes pulsed with the indicated doses of hgp10025–33. 
Unpulsed splenocytes were used as controls. Data shown are representative 
of two independent experiments. 
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tion, considerable differences were observed in lymphode-
pleted versus lymphoreplete recipients (Fig. 1, f–i). pmel-1
cells from lymphodepleted animals produced greater
amounts of IFN-
 
 
 
, IL-2, granulocyte-macrophage CSF, and
TNF-
 
 
 
, as well as macrophage inflammatory protein–1
 
 
 
and regulated on activation, normal T cell expressed and se-
creted (not depicted) 6 d after transfer. Thus, the lym-
phopenic environment induces qualitative rather than quan-
titative improvements of adoptively transferred T cells.
We sought to more completely understand the mecha-
nism of increased CD8
 
 
 
 T cell function after transfer into an
ablated recipient. T reg cells are involved in maintaining im-
munological tolerance to self/tumor antigens (16–20). Exper-
iments using genetic knockouts of T reg cells as well as the
add-back of these cells has incontrovertibly indicated their
critical regulatory role in the antitumor activities of pmel-1
cells (21). We have extended these findings by exploring the
role of TBI in mice devoid of T reg cells. The tripartite regi-
Figure 2. Even in the absence of T reg cells, ablation enhances 
antitumor efficacy of adoptively transferred T cells. (a) Ablation 
augments tumor responses in Rag1 /  mice. TBI or nonirradiated Rag1 /  
mice bearing 14-d-old established s.c. B16 tumors were left untreated or 
received adoptive transfer of 106 cultured pmel-1 T cells in conjunction 
with rFPhgp100 vaccination and rhIL-2. Values represent the mean   
SEM. (b) Ablation augments tumor responses in MHC class II /  mice. TBI 
or nonirradiated MHC class II /  mice bearing 14-d-old established s.c. 
B16 tumors were left untreated or received adoptive transfer of 106 
cultured pmel-1 T cells in conjunction with rFPhgp100 vaccination and 
rhIL-2. Values represent the mean   SEM. (c) Ablation of mice genetically 
devoid of T reg cells augments autoimmunity. 30 d after treatment, mice 
were evaluated in a blinded fashion for the development of vitiligo. The 
percentages of mice with vitiligo are shown.
Figure 3. Removal of NK cells enhances antitumor efficacy of 
adoptively transferred T cells. (a) Irradiation or administration of NK1.1 
antibody efficiently depletes NK cells. Absolute numbers of NK1.1  cells in 
the blood of tumor-bearing TBI Rag-1 /  mice and nonirradiated Rag-1 /  
mice treated with NK1.1 antibody or Ig2aK antibody. Results are shown 3 d 
after the administration of 106 cultured pmel-1 T cells in conjunction with 
rFPhgp100 vaccination and rhIL-2. Values represent the mean   SEM. 
(b) Removal of NK cells by antibody or by irradiation enhances antitumor 
efficacy of adoptively transferred T cells. Rag-1 /  mice bearing 9-d-old 
established s.c. B16 tumors received TBI or antibodies (anti-NK1.1 or Ig2aK 
antibody). Mice then received adoptive transfer of 106 cultured pmel-1 
T cells in conjunction with rFPhgp100 vaccination and rhIL-2 or were left 
untreated. Values represent the mean   SEM. (c) The genetic depletion of 
T cells, B cells, and NK cells recapitulates the effect of TBI. Rag-2 / / C
 /  
mice bearing 8-d-old established s.c. B16 tumors were either left untreated 
or received TBI. Where designated, mice received adoptive transfer of 106 
cultured pmel-1 T cells in conjunction with rFPhgp100 vaccination and 
rhIL-2. Irradiation improved antitumor responses in control WT mice (not 
depicted). Values represent the mean   SEM. 
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men was administered to irradiated or nonirradiated tumor-
bearing Rag-1
 
 
 
/
 
 
 
 mice and MHC class II
 
 
 
/
 
 
 
 mice. We
found that irradiation significantly augmented the antitumor
efficacy of our treatment even in mice lacking endogenous T
reg cells (P 
 
  
 
0.05; Fig. 2, a and b). Similar results were ob-
served in other knockout mice devoid of T reg cells, such as
CD4
 
 
 
/
 
 
 
 (unpublished data). Enhanced autoimmune vitiligo
was observed in irradiated versus nonirradiated mice geneti-
cally devoid of T reg cells (Rag-1
 
 
 
/
 
 
 
, MHC class II
 
 
 
/
 
 
 
, and
CD4
 
 
 
/
 
 
 
; P 
 
 
 
 0.0001) 1 mo after therapy (Fig. 2 c). These
data suggested that the mere removal of T reg cell immune
suppression is not the only mechanism accountable for the
enhanced immune responses observed after irradiation.
IL-7 and IL-15 have supportive roles in the survival and
proliferation of adoptively transferred T cells (1, 2, 4, 23, 24).
Other immune cells may serve as sinks for these cytokines.
Because we found that radiation improved treatment in ex-
periments using Rag1
 
 
 
/
 
 
 
 mice, which lack both T cells and
B cells but have NK cells, we hypothesized that NK cells
may serve as sinks for cytokines. It is known that IL-15 is re-
quired for the survival of NK cells (25, 26). To determine
whether NK cells were sinks in Rag-1
 
 
 
/
 
 
 
 mice, we tested
NK cell depletion using anti-NK1.1 antibody in mice that re-
ceived our tripartite regimen with or without TBI. 3 d after
ACT, high absolute numbers of NK cells were found in the
blood of nonirradiated mice. Fewer NK cells were detected in
either irradiated or NK-depleted Rag1
 
 
 
/
 
 
 
 mice (isotype-
treated vs. irradiated Rag-1
 
 
 
/
 
 
 
 mice, P
 
 
 
  
 
0.0013; isotype-
treated vs. NK-depleted Rag-1
 
 
 
/
 
 
 
 mice, P 
 
  
 
0.002; Fig. 3 a).
No significant differences (P 
 
 
 
 0.05) in NK cell numbers
were found between irradiated and NK-depleted Rag-1
 
 
 
/
 
 
 
mice. As shown in Fig. 2 a, we again observed increased re-
sponses in irradiated compared with nonirradiated Rag-1
 
 
 
/
 
 
 
mice (P 
 
  
 
0.0172; Fig. 3 b). Astonishingly, merely removing
NK cells with an mAb significantly improved ACT (isotype-
treated vs. NK-depleted Rag-1
 
 
 
/
 
 
 
 mice, P 
 
  
 
0.0264) and
was as effective as irradiation (Fig. 3 b). These data indicated
that in the absence of endogenous T reg cells, the removal of
NK cells results in the enhancement antitumor efficacy of
adoptively transferred CD8
 
 
 
 T cells.
To more definitively assess the role of cellular sinks in
our model, we administered pmel-1 cells in conjunction
with vaccine and IL-2 into TBI or nonirradiated Rag-2
 
 
 
/
 
 
 
/
 
 
 
C
 
 
 
/  mice. The mice lack T cells, B cells, and, most impor-
tantly, NK cells. We did not observe an improved treatment
outcome after irradiation in Rag-2 / / C
 /  mice, which
lack all cellular immune components dependent on  C cy-
tokines. Collectively, these finding suggest that endogenous
cellular components, including NK cells, act as cellular sinks
for cytokines capable of activating antitumor responses.
To more precisely determine the role of  C cytokines,
we evaluated our regimen in WT, IL-15 / , IL-7 / , and
IL-7 / IL-15 /  tumor-bearing mice with or without TBI.
The enhancement of the treatment derived from TBI was
partially abrogated on ACT into IL-15 /  (P   0.0009; Fig.
4 b). A slight impairment, not reaching statistical significance
(P   0.05), was seen in mice deficient of IL-7 (not de-
picted). Most importantly, treatment was dramatically im-
paired into mice deficient of both IL-7 and IL-15 (WT vs.
IL-7 / IL-15 / , P   0.0001; IL-15 /  vs. IL-7 / IL-15 / ,
P   0.0003; Fig. 4 b). The lack of both these cytokines
completely abrogated the benefit of the ablation; there were
Figure 4. Increased access to supportive endogenous cytokines into 
irradiated hosts enhances antitumor efficacy of transferred T cells. 
(a and b) Treatment is impaired in irradiated mice genetically deficient in 
IL-15 or IL-7 and IL-15 versus WT mice. WT, IL-15 / , or IL-7 / IL-15 /  
mice bearing 9-d-old established s.c. B16 tumors were left untreated or 
received adoptive transfer of 106 cultured pmel-1 T cells in conjunction 
with rFPhgp100 vaccination and rhIL-2 with or without TBI. Values represent 
the mean   SEM. (c and d) Absence of both IL-7 and IL-15 impaired prolif-
erative responses of adoptively transferred T cells. Absolute numbers of 
adoptively transferred pmel-1 cells (CD8 Thy1.1 ) in the spleens of tumor-
bearing, nonirradiated WT, IL-15 / , or IL-7 / IL-15 /  mice (c). Absolute 
numbers of adoptively transferred pmel-1 cells (CD8 Thy1.1 ) in the spleens 
of tumor-bearing, irradiated WT, IL-15 / , or IL-7 / IL-15 /  mice (d). 
(e–h) Increased access to IL-7 and IL-15 enhances effector functions of 
adoptively transferred T cells. 6 d after adoptive transfer pmel-1 thy1.1  
cells were isolated from the spleens of TBI WT, IL-15 / , or IL-7 / IL-15 /  
mice and co-cultured with irradiated splenocytes pulsed with the indicated 
doses of hgp10025–33. Unpulsed splenocytes were used as controls. Because 
of the limited numbers of cells isolated from IL-7 / IL-15 /  mice, pmel-1 
cells were tested only against 1  g/ml of peptide and unpulsed control.JEM VOL. 202, October 3, 2005 911
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no significant differences (P   0.05) in tumor treatment in
nonirradiated WT mice versus irradiated IL-7 / IL-15 / 
mice. In contrast, the absence of IL-7 and IL-15 did not in-
fluence the treatment in mice that did not receive TBI.
These homeostatic cytokines may not be limiting in the
nonirradiated setting (Fig. 4 a). Thus, endogenous leuko-
cytes appear to compete with the transferred T cells for sup-
portive cytokines in nonirradiated hosts.
To determine whether adoptively transferred CD8  T
cells underwent quantitative or qualitative changes in the
presence of IL-7 and IL-15, pmel-1 thy.1.1 T cells were ad-
ministered in conjunction with vaccine and IL-2 into IL-
15 /  and IL-7 / IL-15 /  with or without TBI. Again,
we did not observe higher numbers of pmel-1 cells in irradi-
ated mice compared with nonirradiated controls (Fig. 4, c
and d). IL-15 was required to maintain the complete func-
tionality of CD8  T cells but not the numbers of pmel-1 T
cells (Fig. 4, c–h). These findings are consistent with the
concept that IL-7 can maintain the proliferation and sur-
vival, but not the function, of adoptively transferred cells in
IL-15 /  mice. Most importantly, pmel-1 cells were pro-
foundly impaired in both quantity and quality when IL-7
and IL-15 were absent (Fig. 4, c–h). Conversely, the addi-
tion of exogenous IL-7 and IL-15 alone or in combination
with our tripartite regimen increased antitumor responses
(Fig. S2, a–d, available at http://www.jem.org/cgi/content/
full/jem.20050732/DC1). These data demonstrate that IL-
15 and IL-7 are critical for sustaining the proliferation and
function of transferred T cells.
Collectively, these findings demonstrate that a key
mechanism underlying the enhanced function of ACT ther-
apies after lymphodepletion is the transient eradication of
cellular sinks and the resultant increase in the availability of
homeostatic cytokines, which in turn results in the augmen-
tation in the function of adoptively transferred T cells. The
ability of T cells to receive these signals maybe critically de-
pendent on their state of differentiation; less-differentiated
cells express higher levels of receptors for key homeostatic
cytokines (27). These findings may furthermore indicate that
limiting access to activating cytokines may be a mechanism
whereby otherwise self-reactive T cells are maintained in a
quiescent state (22). A deeper understanding of the mecha-
nisms underlying the enhanced effectiveness of immuno-
therapy after lymphodepletion may allow us to more pre-
cisely achieve enhanced immunity without the use of
nonspecific modalities such as chemotherapy or TBI, with
all their life-threatening side effects.
MATERIALS AND METHODS
Mice and tumor lines. All mice used in these experiments were bred
and housed at NIH facilities. Female pmel-1 TCR Tg mice (22) were
crossed with C57BL/6-Thy1.1 Tg mice (The Jackson Laboratory) to derive
pmel-Thy1.1 double Tg mice (C57BL/6-pmel-1-Thy1.1 mice; The Jack-
son Laboratory). Female C57BL/6, Rag-1 / , MHC class II /  (The Jack-
son Laboratory), IL-15 / , Rag-2 / / C
 /  (Taconic), IL-7 / , and
IL-7 / IL-15 / mice were used as recipients in ACT experiments. Experi-
ments were conducted with the approval of the NCI Animal Use and Care
Committee. B16-F10 (H-2b), a spontaneous, transplantable gp100  murine
melanoma, was maintained in culture media as previously described (22).
In vitro activation of pmel-1 T cells. pmel-1 splenocytes were iso-
lated as described previously (22) and cultured in the presence of 1  M
hgp10025–33 and culture media containing 30 IU/ml of recombinant human
IL-2 (rhIL-2; Chiron Corp.). Cells were used for ACT 6–7 d after the start
of the culture.
ACT, vaccination, and cytokine administration. 6–12-wk-old mice
(n   5 for all groups) were injected s.c. with 2–5   105 B16-F10 melanoma
cells and treated 10–14 d later with i.v. adoptive transfer of pmel-1 CD8  T
cell in vitro activated–splenocytes. Lymphopenia was induced by sublethal
TBI (5 Gy) of tumor-bearing mice on the day of treatment. NK cells were
depleted by i.p. administration of 100  g/mouse of NA/LE anti-NK1.1
antibody (BD Biosciences) every 3 d for a total of five doses. 100  g/mouse
of NA/LE anti-Ig2aK was used as a control antibody (BD Biosciences).
Mice were vaccinated with 2   107 PFU of a previously described (22) re-
combinant fowlpox virus expressing human gp100 (rFPhgp100; Therion
Biologics). 0–108  g/dose of rhIL-2 (Chiron Corp.), rhIL-7, or rhIL-15
(PeproTech) were administered by i.p. injection twice daily for a total of six
doses. Tumors were measured using calipers, and the products of the per-
pendicular diameters were recorded. All experiments were performed in a
blind, randomized fashion (the measuring investigator had no knowledge of
the experimental group) and performed independently at least twice with
similar results.
Enumeration of adoptively transferred cells, NK cells, and ex vivo
cytokine release assay. At the time points indicated in the figures, adop-
tively transferred pmel-1 thy1.1 cells were enumerated as previously de-
scribed (28). 3 d after treatment, the NIH clinical laboratory determined the
white blood cell count on blood samples. Samples were analyzed by flow
cytometry for Nk1.1 expression by cells. NK cell number was calculated by
multiplying the white blood cell count by the percentage of NK1.1-positive
cells. 6 d after adoptive transfer, pmel-1 thy1.1 cells were also used for cy-
tokine release assay. pmel-1 thy1.1 cells were isolated from splenocytes as
previously described (21) and were co-cultured at a 1:2 ratio with 105 irra-
diated splenocytes pulsed with titrated doses of hgp10025–33 peptide. Un-
pulsed splenocytes were used as negative controls. Supernatants were col-
lected after 18 h and assayed by murine Lincoplex cytokine assay (Linco
Research) or mouse IFN-  (Endogen) ELISA kits.
Statistical analysis. Tumor graphs were examined using the analysis of
variance between groups test.
Online supplemental material. Fig. S1 shows how lymphodepletion
enhances the antitumor activity of adoptively transferred CD8  T cells by
an indirect mechanism rather than directly killing the tumor. Fig. S2 shows
the enhancement of ACT immunotherapy by the exogenous administration
of combinations of IL-2, IL-7, and IL-15. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050732/DC1.
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